Literature DB >> 32769602

Closed Vs. Open Reduction/Salter Innominate Osteotomy for Developmental Hip Dislocation After Age 18 Months: Comparative Survival at 45-Year Follow-up.

Elizabeth J Scott1, Lori A Dolan, Stuart L Weinstein.   

Abstract

BACKGROUND: Despite widespread use of single-stage open reduction and pelvic osteotomy for treatment of developmental dysplasia of the hip (DDH) after walking age, this aggressive strategy remains controversial. We directly compared dislocated hips treated with closed reduction (CR) to those treated with open reduction and Salter innominate osteotomy (OR/IO) to estimate the relative hazard of total hip arthroplasty (THA) and the THA-free survival time.
METHODS: In a series of patients 18 to 60 months of age, 45 patients (58 hips) underwent CR and 58 patients (78 hips) were treated with OR/IO and followed to a minimum 40 years post-reduction. Observations in the survival analysis were censored if no THA had occurred by 48 years. Multivariate Cox regression analysis was used to estimate the hazard of THA given treatment, age, and bilaterality. Complications and additional procedures were noted.
RESULTS: At 48 years of follow-up, 29 (50%) of the hips survived after CR compared with 54 (69%) after OR/IO. At 45 years, the survival probability after OR/IO was 0.63 (95% confidence interval [CI] = 0.50 to 0.78) compared with 0.55 (95% CI = 0.43 to 0.72) after CR. The hazard ratio (HR) of THA was modeled as a function of treatment, age at reduction, and bilaterality. The effect of age and treatment on the outcome of hips in patients with unilateral involvement was minimal. However, age did significantly alter the relationship between treatment and outcome in bilateral cases. In the bilateral group, the predicted HR of THA was lower after CR in hips that were reduced at the age of 18 months (HR = 0.16, 95% CI = 0.04 to 0.64) but higher in those that were reduced at 36 months (HR = 4.23, 95% CI = 2.00 to 8.95). Additional procedures were indicated for 17% and 22% of hips after CR and OR/IO, respectively.
CONCLUSIONS: Osteoarthritis and THA was more likely after CR than OR/IO, but the data do not indicate a difference in unadjusted hip-survival time. In patients with bilateral disease, an older age at reduction was associated with an increased hazard of THA after CR than after OR/IO. Both treatments provided substantial benefit relative to the natural history of DDH, but THA is the expected outcome in middle adulthood. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

Entities:  

Year:  2020        PMID: 32769602     DOI: 10.2106/JBJS.19.01278

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  5 in total

Review 1.  Residual Acetabular Dysplasia in the Reduced Hip.

Authors:  Soroush Baghdadi; Wudbhav N Sankar
Journal:  Indian J Orthop       Date:  2021-09-15       Impact factor: 1.033

Review 2.  DDH in the Walking Age: Review of Patients with Long-Term Follow-Up.

Authors:  Giovanni Lucchesi; Riccardo Sacco; Weizheng Zhou; YiQiang Li; Lianyong Li; Federico Canavese
Journal:  Indian J Orthop       Date:  2021-09-29       Impact factor: 1.033

3.  Demographic and Practice Variability Amongst Indian Centres in a Multicentre Prospective Observational Study on Developmental Dysplasia of the Hip.

Authors:  Deepika Pinto; Alaric Aroojis; Hitesh Shah; Sandeep Patwardhan; K Venkatadass; Chittaranjan Sahu; Emily Schaeffer; Kishore Mulpuri
Journal:  Indian J Orthop       Date:  2021-09-20       Impact factor: 1.033

4.  Narrative Review of Complications Following DDH Treatment.

Authors:  Raghav Badrinath; Caitlin Orner; James D Bomar; Vidyadhar V Upasani
Journal:  Indian J Orthop       Date:  2021-10-23       Impact factor: 1.251

5.  The incidence of avascular necrosis following a cohort of treated developmental dysplasia of the hip in a single tertiary centre.

Authors:  Rahim Nawaz Hussain; Darius Rad; William John Watkins; Clare Carpenter
Journal:  J Child Orthop       Date:  2021-06-01       Impact factor: 1.548

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.